On Tuesday, ARS Pharmaceuticals Inc (NASDAQ: SPRY) opened lower -1.05% from the last session, before settling in for the closing price of $11.89. Price fluctuations for SPRY have ranged from $5.02 to $18.51 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -34.76% over the last five years. Company’s average yearly earnings per share was noted -2.19% at the time writing. With a float of $51.02 million, this company’s outstanding shares have now reached $97.15 million.
The firm has a total of 26 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.97%, operating margin of -2384.0%, and the pretax margin is -1934.75%.
ARS Pharmaceuticals Inc (SPRY) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ARS Pharmaceuticals Inc is 47.50%, while institutional ownership is 42.09%. The most recent insider transaction that took place on Dec 12 ’24, was worth 1,439,124. In this transaction Chief Business Officer of this company sold 117,333 shares at a rate of $12.27, taking the stock ownership to the 136,380 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Chief Business Officer sold 27,272 for $12.06, making the entire transaction worth $328,968. This insider now owns 136,380 shares in total.
ARS Pharmaceuticals Inc (SPRY) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -2.19% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Check out the current performance indicators for ARS Pharmaceuticals Inc (SPRY). In the past quarter, the stock posted a quick ratio of 12.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 444.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.36 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Analysing the last 5-days average volume posted by the [ARS Pharmaceuticals Inc, SPRY], we can find that recorded value of 1.2 million was better than the volume posted last year of 0.83 million. As of the previous 9 days, the stock’s Stochastic %D was 5.60%. Additionally, its Average True Range was 0.86.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 29.72%, which indicates a significant increase from 6.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.70% in the past 14 days, which was lower than the 72.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.53, while its 200-day Moving Average is $11.40. Now, the first resistance to watch is $12.00. This is followed by the second major resistance level at $12.23. The third major resistance level sits at $12.46. If the price goes on to break the first support level at $11.54, it is likely to go to the next support level at $11.31. Should the price break the second support level, the third support level stands at $11.08.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
There are currently 97,185K shares outstanding in the company with a market cap of 1.14 billion. Presently, the company’s annual sales total 30 K according to its annual income of -54,370 K. Last quarter, the company’s sales amounted to 2,070 K and its income totaled -19,130 K.
